Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer models.

Nisa L, Häfliger P, Poliaková M, Giger R, Francica P, Aebersold DM, Charles RP, Zimmer Y, Medová M.

Mol Cancer. 2017 May 22;16(1):93. doi: 10.1186/s12943-017-0660-5.

2.

Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric Cancer.

Francica P, Nisa L, Aebersold DM, Langer R, Bladt F, Blaukat A, Stroka D, Martínez MR, Zimmer Y, Medová M.

Clin Cancer Res. 2016 Nov 1;22(21):5322-5336. Epub 2016 May 16.

3.

Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.

Andreucci E, Francica P, Fearns A, Martin LA, Chiarugi P, Isacke CM, Morandi A.

Oncotarget. 2016 Dec 6;7(49):80543-80553. doi: 10.18632/oncotarget.11826.

4.

Senescence as biologic endpoint following pharmacological targeting of receptor tyrosine kinases in cancer.

Francica P, Aebersold DM, Medová M.

Biochem Pharmacol. 2017 Feb 15;126:1-12. doi: 10.1016/j.bcp.2016.08.022. Epub 2016 Aug 27. Review.

PMID:
27574725
5.

Impact of p53 Status on Radiosensitization of Tumor Cells by MET Inhibition-Associated Checkpoint Abrogation.

Mikami K, Medová M, Nisa L, Francica P, Glück AA, Tschan MP, Blaukat A, Bladt F, Aebersold DM, Zimmer Y.

Mol Cancer Res. 2015 Dec;13(12):1544-53. doi: 10.1158/1541-7786.MCR-15-0022. Epub 2015 Sep 10.

6.

Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation.

Leiser D, Pochon B, Blank-Liss W, Francica P, Glück AA, Aebersold DM, Zimmer Y, Medová M.

FEBS Lett. 2014 Mar 3;588(5):653-8. doi: 10.1016/j.febslet.2013.12.025. Epub 2014 Jan 17.

7.

The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variants.

Medová M, Pochon B, Streit B, Blank-Liss W, Francica P, Stroka D, Keogh A, Aebersold DM, Blaukat A, Bladt F, Zimmer Y.

Mol Cancer Ther. 2013 Nov;12(11):2415-24. doi: 10.1158/1535-7163.MCT-13-0151. Epub 2013 Sep 23.

Supplemental Content

Loading ...
Support Center